Welcome : Guest

BIORESORBABLE SCAFFOLDS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Bioresorbable Scaffolds in US$ Thousand. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as -

Abbott Laboratories
Amaranth Medical, Inc.
Arterial Remodeling Technologies SA
BIOTRONIK SE & Co. KG
Elixir Medical Corp.
Kyoto Medical Planning Co., Ltd.

Click here to request a full list of companies covered in the report...

Code: MCP-6396
Price: $4500
Companies: 17
Pages: 126
Date: September 2017
Market Data Tables: 31
  Status: * New Report



TABLE OF CONTENTS


  BIORESORBABLE SCAFFOLDS (Complete Report) Pages : 126   | $4500

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   BioResorbable Scaffolds/Stents – A Prelude.....II-12$200
   Clinical Characteristics of Various Coronary Stents.....II-3
Bioresorbable Vascular Scaffolds: Advantages and Challenges.....II-3
Evolution of Coronory Stents.....II-3
1$100
   Global Coronory Stents Market – A Few Key Facts.....II-4
Bioresorbable Stents – A Revolutionary Technology, Riddled with Controversies.....II-4
1$100
   Abbott Stops Sales of the Once Promising ‘Absorb’ Bioresorbable Stents due to Adverse
  Events.....II-5
1$100
   Impact of Abbott’s Withdrawal of Absorb on the Bioresorbable Stent Industry.....II-62$200
   Challenges in Next-generation BVS Development.....II-81$100
   Desired Features of Bioresorbable Stents.....II-91$100
   Other Available Bioresorbable Scaffolds Exhibit Potential.....II-10
Approved Bioresorbable Scaffolds.....II-10
Magmaris Exhibits Stability and Safety with Lack of Scaffold Thrombosis
  Occurrence.....II-10
1$100
   Fantom from REVA Medical.....II-11
DESolve from Elixir Medical.....II-11
1$100
   ART from Arterial Remodeling Technologies.....II-12
Bioresorbable Scaffolds in Pipeline.....II-12
1$100
   Current & Future Analysis.....II-13
Developing Countries – Hot Spots for Growth.....II-13
1$100
   Absorb Bioresorbable Scaffold/Stent Trials – Adverse Outcomes after Two Years of
  Placement.....II-14
The ABSORB III Trials.....II-14
1$100
   Performance of Absorb in Smaller Vessels.....II-151$100
   Global Menace of Coronary Artery Disease (CAD) – A Major Growth Driver.....II-16
Table 1: Global Annual Medical Cost of CVD in the United States: 2015-2030 (includes corresponding Graph/Chart).....II-16

Table 2: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart).....II-16
1$350
   Table 3: Top 10 Causes of Death Globally: 2015 (includes corresponding Graph/Chart).....II-171$350
   Table 4: Top 10 Causes of Death in Low-Income Economies: 2015 (includes corresponding Graph/Chart).....II-181$350
   Table 5: Top 10 Causes of Death in Lower-Middle-Income Economies: 2015 (includes corresponding Graph/Chart).....II-191$350
   Table 6: Top 10 Causes of Death in Upper-Middle-Income Economies: 2015 (includes corresponding Graph/Chart).....II-201$350
   Table 7: Top 10 Causes of Death in High-Income Economies: 2015 (includes corresponding Graph/Chart).....II-21
Ageing Demographics and Longer Life Expectancy Bolsters Market Growth.....II-21
1$350
   Table 8: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart).....II-221$350
   Table 9: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart).....II-23
Rising Middle Class Population Aids Growth.....II-23
1$350
   Table 10: Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P (includes corresponding Graph/Chart).....II-241$350
   Rising Healthcare Expenditure: Opportunities in Store.....II-25
Table 11: Top Countries with the Highest Per Capita Healthcare Spending (2014) (includes corresponding Graph/Chart).....II-25
1$350
   Table 12: Healthcare Spending as % of GDP by Geographic Region: 2016 (includes corresponding Graph/Chart).....II-26
Risk of CAD in Obesity Offers Prospects for Coronary Stenting.....II-26
1$350
   Table 13: Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025 (includes corresponding Graph/Chart).....II-271$350
   Table 14: Severely Obese Population (in Thousands) Worldwide by Country: 2014 & 2025 (includes corresponding Graph/Chart).....II-28
Diabetics at Higher Risk of Heart Diseases.....II-28
2$350
   Table 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040 (includes corresponding Graph/Chart).....II-301$350
   Table 16: Global Prevalence (%) of Diabetes in Adults (20-79) by Region: 2015 & 2040 (includes corresponding Graph/Chart).....II-31

Table 17: Global Prevalence of Diabetes by Gender (2015 & 2040): Number of Adults Diagnosed with Diabetes (in Million) for Men and Women (includes corresponding Graph/Chart).....II-31
1$350
   Table 18: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2015 & 2040 (includes corresponding Graph/Chart).....II-32
The Hypertension-Cholesterol Link to Drive Demand.....II-32
1$350
   Table 19: Worldwide Prevalence of Hypertension (BP>=140 OR DBP>=90) (age-standardized estimate) among Male and Female (2014): Breakdown by Select Countries.....II-331$350
   Spurt in Medical Tourism Offers Growth Opportunities.....II-34
Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer
  Stents.....II-34
1$100
   Metal Stents Vis-à-vis Other Stents.....II-35
Alternative Therapies/Devices: Threats to Coronary Stents.....II-35
Cell Transplantation – A Threat to Coronary Stents.....II-35
1$100
   Falcon from Abbott.....II-36
Fortitude, Aptitude, and Magnitude from Amaranth.....II-36
Renuvia from Boston Scientific.....II-36
Ideal from Xenogenics.....II-36
MeRes from Meril.....II-36
1$100
   Mirage from Manli Cardiology.....II-37
Xinsorb from HuaAn Biotechnology.....II-37
Firesorb from MicroPort.....II-37
1$100
   Unity from QualiMed.....II-381$100
   The United States.....II-39
Europe.....II-39
Australia.....II-39
1$100
   Coronary Artery Disease (CAD) – A Perspective.....II-40
Causes and Symptoms.....II-40
Treatment Options for Coronary Artery Disease.....II-40
1$100
   Percutaneous Coronary Intervention (PCI).....II-41
Coronary Stenting.....II-41
Types of Coronary Stents.....II-41
Bare Metal Stents (BMS).....II-41
1$100
   Drug Eluting Stents (DES).....II-42
Bioresorbable Scaffolds.....II-42
Design and Composition of Bioresorbable Scaffolds.....II-42
1$100
   Different Types of Bioresorbable Scaffolds.....II-43
Metallic Bioresorbable Scaffolds.....II-43
Polymer Bioresorbable Scaffolds.....II-43
Degradation Period of Select Bioabsorbable Materials.....II-43
1$100
   Challenges.....II-441$100
   Other Treatment Options for Coronary Heart Disease.....II-45
Coronary Artery Bypass Grafting (CABG).....II-45
Minimally Invasive Direct Coronary Artery Bypass (MIDCAB).....II-45
TransMyocardial Laser Revascularization (TMR).....II-45
Peripheral Arterial Disease: Understanding the Stealthy Peril.....II-45
1$100
   Treatment for PAD.....II-46
Lifestyle Changes.....II-46
Medication.....II-46
1$100
   Surgery.....II-47
Stenting- A Treatment Option for PAD.....II-47
1$100
   The DGCI Warns Against the Use of Absorb in 2.5 mm or Narrower Blood Vessels.....II-48
Akesys and Elixir Medical Completes Successful Implantation of PRAVA™ for Peripheral
  Vascular Disease.....II-48
Elixir Medical Showcases DESolve CX and AMITY® at EuroPCR 2016.....II-48
Micell Technologies Announces Commercialization of MiStent SES® in Europe.....II-48
1$100
   Elixir Medical Confirms Excellent 5-Year Clinical Data for DESolve®.....II-49
Amaranth Medical Announces Nine-month Follow-up RENASCENT-II Study Results of the
  APTITUDE®.....II-49
Abbott's Absorb™ Receives Approval as the Japan’s First Fully Dissolving Heart
  Stent.....II-49
Amaranth Medical Initiates Clinical Study for MAGNITUDE™ Sirolimus-Eluting
  Bioresorbable Scaffold.....II-49
Abbott's Absorb™ Receives Health Canada Approval.....II-49
BIOTRONIK Obtains CE Mark Approval for Magmaris, the First Magnesium Bioresorbable
  Scaffold.....II-49
1$100
   Abbott's Absorb™ Receives FDA Approval.....II-50
US FDA Approves Boston Scientific’s SYNERGY™ BP-DES.....II-50
Abbott Receives CE Mark for Absorb GT1™.....II-50
ART Receives CE Mark Clearance for its Pure Bioresorbable Scaffold.....II-50
1$100
   Abbott Laboratories (USA).....II-51
Amaranth Medical, Inc. (USA).....II-51
1$100
   Arterial Remodeling Technologies SA (France).....II-52
BIOTRONIK SE & Co. KG (Germany).....II-52
1$100
   Elixir Medical Corp. (USA).....II-53
Kyoto Medical Planning Co., Ltd. (Japan).....II-53
REVA Medical, Inc. (USA).....II-53
2$200
   Table 20: World Current and Future Analysis for Bioresorbable Scaffolds by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-551$350
   Table 21: World 9-Year Perspective for Bioresorbable Scaffolds by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2017 and 2024 (includes corresponding Graph/Chart).....II-561$350
   A. Market Analysis.....III-1
Abbott’s Decision to End Absorb Sales Brings the US Bioresorbable Scaffolds Market
  to a Standstill.....III-1
1$95
   Increasing Incidence of CAD to Drive the Need for More Research into Bioresorbable
  Stents.....III-2
Rising CVD Incidence – A Major Growth Driver.....III-2
1$95
   Table 22: Cardiovascular Disease Incidence in the US by Gender & Age Group (per 1,000 Adults) (includes corresponding Graph/Chart).....III-3

Table 23: Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart).....III-3
1$200
   Ageing Population – A Vital Demography.....III-4
Table 24: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart).....III-4
1$200
   Clinical Trials and Product Approvals.....III-51$95
   Strategic Corporate Development.....III-6
Select Key Players.....III-6
2$190
   B. Market Analytics.....III-8
Table 25: The US Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024.....III-8
1$200
   A. Market Analysis.....III-9
The Largest Market for Bioresorbable Scaffolds Globally.....III-9
Abbott Restricts Availability of Absorb.....III-9
Growth Drivers.....III-9
Cardiovascular Disease in Europe – A Perspective.....III-9
1$95
   Europe – A Highly Diverse Market.....III-10
Absorbable Stents & the Controversies Surrounding Them.....III-10
1$95
   Ageing Population Boosts Demand for Biodegradable Stents.....III-11
Table 26: European Country-wise Statistics of 65+ Population as % of Total Population: As on January 1, 2015 (includes corresponding Graph/Chart).....III-11
1$200
   Strategic Corporate Developments.....III-12
Product Approvals.....III-12
Key Players.....III-12
2$190
   B. Market Analytics.....III-14
Table 27: European Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-14
1$200
   A. Market Analysis.....III-15
The Fastest Growing Market for Bioresorbable Scaffolds.....III-15
Growth Drivers.....III-15
1$95
   Aging Populace – Potential Opportunities.....III-16
Table 28: Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart).....III-16
Asia-Pacific – A Price Sensitive Market.....III-16
India & China Offer Significant Growth Opportunities.....III-16
1$200
   Table 29: China and India Lead Global Population (2015): Table Depicting China and India’s Huge Population Vis-a-Vis Other Countries’ Population (in Millions) by Age Group (includes corresponding Graph/Chart).....III-171$200
   Focus on Select Markets.....III-18
Australia.....III-18
Abbott Vascular Australia Issues “Hazard Alert” for Absorb BVS.....III-18
India.....III-18
Drug Regulators Issues Warning Regarding Usage of Absorb Stent.....III-18
1$95
   India Imposes Price Controls on Stents, Boosting Chinese Imports.....III-19
Price Ceiling of Coronary Stents in India.....III-19
1$95
   India – A Highly Potential Market for CVD Products.....III-20
Unethical Medical Practices Mar Business Prospects.....III-20
Japan.....III-20
Prospects Weighed down by Regulatory Entanglements.....III-20
1$95
   Bioresorbable Scaffolds Status in Japan.....III-21
China.....III-21
Healthcare Reforms to Propel Stent Market.....III-21
Strategic Corporate Development.....III-21
Kyoto Medical Planning Co., Ltd. (Japan) – A Key Player.....III-21
1$95
   B. Market Analytics.....III-22
Table 30: Asia-Pacific Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-22
1$200
   A. Market Analysis.....III-23
Product Approvals.....III-23
1$95
   B. Market Analytics.....III-24
Table 31: Rest of World Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-24
1$200
  
Total Companies Profiled: 17 (including Divisions/Subsidiaries - 18)

Region/Country Players

The United States 6 Japan 1 Europe 5 France 1 Germany 2 The United Kingdom 1 Rest of Europe 1 Asia-Pacific (Excluding Japan) 6
Click here to request a full table of contents and more details on this project.